Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Ana... von Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Phelan, James D., Simard, Jillian, Muppidi, Jagan R., Thomas, Craig J., Ceribelli, Michele, Tosto, Frances Anne, Pradhan, Amynah, Juanitez, Anna Marie, Steinberg, Seth M., Jaffe, Elaine S., Roschewski, Mark, Staudt, Louis M., Wilson, Wyndham H.

Volltext

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molec... von Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Miljkovic, Milos D., Phelan, James D., Muppidi, Jagan R., Thomas, Craig J., Ceribelli, Michele, Juanitez, Anna Marie, Pradhan, Amynah, Hillsman, Amy, Steinberg, Seth M., Jaffe, Elaine S., Roschewski, Mark, Staudt, Louis M., Wilson, Wyndham H.

Volltext

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease von Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Phelan, James D., Simard, Jillian, Muppidi, Jagan R., Thomas, Craig J., Ceribelli, Michele, Tosto, Frances Anne, Farah, Rafic J., Lee, Seung Tae, Pradhan, Amynah, Juanitez, Anna Marie, Steinberg, Seth M., Jaffe, Elaine S., Roschewski, Mark, Staudt, Louis M., Wilson, Wyndham H.

Volltext

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma von Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Phelan, James D., Huang, Da Wei, Wright, George, Simard, Jillian, Muppidi, Jagan, Thomas, Craig J., Ceribelli, Michele, Tosto, Frances A., Yang, Yandan, Xu, Weihong, Davies-Hill, Theresa, Pack, Svetlana D., Peer, Cody J., Arisa, Oluwatobi, Mena, Esther, Lindenberg, Liza, Bergvall, Ethan, Portell, Craig A., Farah, Rafic J., Lee, Seung Tae, Pradhan, Amynah, Morrison, Candis, Tadese, Atekelt, Juanitez, Anna Marie, Lu, Crystal, Jacob, Allison, Simmons, Heidi, Figg, William D., Steinberg, Seth M., Jaffe, Elaine S., Roschewski, Mark, Staudt, Louis M., Wilson, Wyndham H.

Volltext

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphom... von Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Phelan, James D, Huang, Da Wei, Wright, George, Simard, Jillian, Muppidi, Jagan R., Thomas, Craig J., Ceribelli, Michele, Tosto, Frances A, Yang, Yandan, Xu, Weihong, Davies-Hill, Theresa, Pack, Svetlana, Peer, Cody J, Arisa, Oluwatobi, Mena, Esther, Lindenberg, Maria L., Bergvall, Ethan, Portell, Craig A., Farah, Rafic J, Lee, Seung Tae, Pradhan, Amynah, Morrison, Candis, Tadese, Atekelt, Juanitez, Anna M, Lu, Crystal, Jacob, Allison P., Simmons, Heidi, Figg, William D, Steinberg, Seth M., Jaffe, Elaine S, Roschewski, Mark, Staudt, Louis M., Wilson, Wyndham H

Volltext

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis von Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Miljkovic, Milos D., Muppidi, Jagan R., Portell, Craig A., Farah, Rafic, Lee, Seung Tae, Juanitez, Anna Marie, Chou, Lydia L., Steinberg, Seth M., Jaffe, Elaine S., Staudt, Louis, Roschewski, Mark, Wilson, Wyndham

Volltext

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis von Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Miljkovic, Milos D., Phelan, James D., Muppidi, Jagan R., Thomas, Craig J., Ceribelli, Michele, Tosto, Frances Anne, Portell, Craig A., Farah, Rafic J., Lee, Seung Tae, Juanitez, Anna Marie, Steinberg, Seth M., Jaffe, Elaine S., Roschewski, Mark, Staudt, Louis M., Wilson, Wyndham H.

Volltext

MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL) von Lakhotia, Rahul, Pittaluga, Stefania, Phelan, James, Yang, Yandan, Davies-Hill, Theresa, Simard, Jillian, Muppidi, Jagan, Huang, Da Wei, Thomas, Craig, Ceribelli, Michele, Tosto, Frances, Pradhan, Amynah, Juanitez, Anna, Rimsza, Lisa, Jacob, Allison, Simmons, Heidi, Steinberg, Seth, Jaffe, Elaine, Staudt, Louis, Roschewski, Mark, Wilson, Wyndham, Melani, Christopher

Volltext

POSTER: MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL) von Lakhotia, Rahul, Pittaluga, Stefania, Phelan, James, Yang, Yandan, Davies-Hill, Theresa, Simard, Jillian, Muppidi, Jagan, Huang, Da Wei, Thomas, Craig, Ceribelli, Michele, Tosto, Frances, Pradhan, Amynah, Juanitez, Anna, Rimsza, Lisa, Jacob, Allison, Simmons, Heidi, Steinberg, Seth, Jaffe, Elaine, Staudt, Louis, Roschewski, Mark, Wilson, Wyndham, Melani, Christopher

Volltext

Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies von Melani, Christopher, Gordon, Max, Lakhotia, Rahul, Pittaluga, Stefania, Simard, Jillian, Muppidi, Jagan, Phelan, James D., Pack, Svetlana, Pradhan, Amynah, Morrison, Candis, Tadese, Atekelt, Juanitez, Anna M., Johnson, Amy J., Frigault, Melanie M., Hamdy, Ahmed, Roschewski, Mark, Staudt, Louis M., Wilson, Wyndham H.

Volltext